JPS61205219A - 生物学的に活性なヒト第8因子断片からなる抗血友病剤およびその製造方法 - Google Patents

生物学的に活性なヒト第8因子断片からなる抗血友病剤およびその製造方法

Info

Publication number
JPS61205219A
JPS61205219A JP61045506A JP4550686A JPS61205219A JP S61205219 A JPS61205219 A JP S61205219A JP 61045506 A JP61045506 A JP 61045506A JP 4550686 A JP4550686 A JP 4550686A JP S61205219 A JPS61205219 A JP S61205219A
Authority
JP
Japan
Prior art keywords
thr
arg
tyr
factor
daltons
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP61045506A
Other languages
English (en)
Japanese (ja)
Other versions
JPH0547524B2 (cg-RX-API-DMAC7.html
Inventor
ラース‐オロフ・アンデルソン
ナンナ・フオルスマン
ケルステイン・エツバ.イングリード・ラーセン
アンネリエ・ビルイツタ・ルンデイン
パヴル・ボーダン
インガ・ヘレナ・サンドベルイ
カリン・マーガレータ・セヴエリン
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pfizer Health AB
Original Assignee
Kabi Pharmacia AB
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=20359353&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=JPS61205219(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Kabi Pharmacia AB filed Critical Kabi Pharmacia AB
Publication of JPS61205219A publication Critical patent/JPS61205219A/ja
Publication of JPH0547524B2 publication Critical patent/JPH0547524B2/ja
Granted legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/745—Blood coagulation or fibrinolysis factors
    • C07K14/755—Factors VIII, e.g. factor VIII C (AHF), factor VIII Ag (VWF)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • E—FIXED CONSTRUCTIONS
    • E02—HYDRAULIC ENGINEERING; FOUNDATIONS; SOIL SHIFTING
    • E02D—FOUNDATIONS; EXCAVATIONS; EMBANKMENTS; UNDERGROUND OR UNDERWATER STRUCTURES
    • E02D31/00—Protective arrangements for foundations or foundation structures; Ground foundation measures for protecting the soil or the subsoil water, e.g. preventing or counteracting oil pollution
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/827—Proteins from mammals or birds
    • Y10S530/829—Blood
    • Y10S530/83—Plasma; serum
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S930/00—Peptide or protein sequence
    • Y10S930/01—Peptide or protein sequence
    • Y10S930/10—Factor VIII, AHF; related peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Hematology (AREA)
  • Structural Engineering (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Environmental & Geological Engineering (AREA)
  • Hydrology & Water Resources (AREA)
  • General Life Sciences & Earth Sciences (AREA)
  • Mining & Mineral Resources (AREA)
  • Paleontology (AREA)
  • Civil Engineering (AREA)
  • General Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Diabetes (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
JP61045506A 1985-03-05 1986-03-04 生物学的に活性なヒト第8因子断片からなる抗血友病剤およびその製造方法 Granted JPS61205219A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
SE8501050A SE8501050D0 (sv) 1985-03-05 1985-03-05 Biologically active fragments of human antihemophilic factor and method for preparation thereof
SE8501050-2 1985-03-05

Publications (2)

Publication Number Publication Date
JPS61205219A true JPS61205219A (ja) 1986-09-11
JPH0547524B2 JPH0547524B2 (cg-RX-API-DMAC7.html) 1993-07-19

Family

ID=20359353

Family Applications (1)

Application Number Title Priority Date Filing Date
JP61045506A Granted JPS61205219A (ja) 1985-03-05 1986-03-04 生物学的に活性なヒト第8因子断片からなる抗血友病剤およびその製造方法

Country Status (10)

Country Link
US (2) US4749780A (cg-RX-API-DMAC7.html)
EP (1) EP0197901B1 (cg-RX-API-DMAC7.html)
JP (1) JPS61205219A (cg-RX-API-DMAC7.html)
AT (1) ATE65505T1 (cg-RX-API-DMAC7.html)
CA (1) CA1341497C (cg-RX-API-DMAC7.html)
DE (1) DE3680368D1 (cg-RX-API-DMAC7.html)
DK (1) DK164282B (cg-RX-API-DMAC7.html)
HK (1) HK15293A (cg-RX-API-DMAC7.html)
SE (1) SE8501050D0 (cg-RX-API-DMAC7.html)
SG (1) SG1893G (cg-RX-API-DMAC7.html)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5362854A (en) * 1983-03-31 1994-11-08 Scripps Clinic & Research Foundation Factor VIII coagulant polypeptides: method of making
US7138505B1 (en) 1984-01-12 2006-11-21 Novartis Vaccines And Diagnostics, Inc. Factor VIII:C nucleic acid molecules
SE8501050D0 (sv) * 1985-03-05 1985-03-05 Kabivitrum Ab Biologically active fragments of human antihemophilic factor and method for preparation thereof
KR910006424B1 (ko) * 1985-08-21 1991-08-24 인코텍스 비.브이 편성브리프(brief) 제조방법
US5198349A (en) * 1986-01-03 1993-03-30 Genetics Institute, Inc. Method for producing factor VIII:C and analogs
FI98829C (fi) * 1986-01-27 1997-08-25 Chiron Corp Menetelmä rekombinoidun proteiinikompleksin valmistamiseksi, jolla on humaanitekijä VIII:C-aktiivisuutta
US5422260A (en) * 1986-05-29 1995-06-06 Genetics Institute, Inc. -Legal Affairs Human factor VIII:c muteins
EP0251843A1 (fr) * 1986-06-06 1988-01-07 Transgene S.A. Procédé de préparation de facteur VIII à partir de cellules de mammifères
FR2613379B2 (fr) * 1987-04-03 1990-04-06 Transgene Sa Procede de preparation de fragments du facteur viii a partir de cellules de mammiferes
JP2593500B2 (ja) * 1986-06-24 1997-03-26 ノルデイスク ゲントフテ エー/エス ▲viii▼因子フラグメントの凝固活性複合物の製造方法
US4980456A (en) * 1987-04-06 1990-12-25 Scripps Clinic And Research Foundation Recombinant factor VIIIC derived fragments
US6346513B1 (en) 1987-06-12 2002-02-12 Baxter Trading Gmbh Proteins with factor VIII activity: process for their preparation using genetically-engineered cells and pharmaceutical compositions containing them
IE69026B1 (en) 1987-06-12 1996-08-07 Immuno Ag Novel proteins with factor VIII activity process for their preparation using genetically-engineered cells and pharmaceutical compositions containing them
ATE168059T1 (de) * 1992-04-06 1998-07-15 Pressmaster Tool Ab Crimp-werkzeug
ATE198277T1 (de) * 1992-10-02 2001-01-15 Genetics Inst Zusammensetzung, welche den koagulationsfaktor viii beinhaltet; verfahren zu deren herstellung und die benutzung eines oberflächenaktiven stoffes als stabilisator
US5576291A (en) * 1993-09-13 1996-11-19 Baxter International Inc. Activated factor VIII as a therapeutic agent and method of treating factor VIII deficiency
SE9303601D0 (sv) * 1993-11-01 1993-11-01 Kabi Pharmacia Ab Improved cell cultivation method and medium
US6288030B1 (en) 1993-12-22 2001-09-11 Amgen Inc. Stem cell factor formulations and methods
IL113010A0 (en) * 1994-03-31 1995-10-31 Pharmacia Ab Pharmaceutical formulation comprising factor VIII or factor ix with an activity of at least 200 IU/ml and an enhancer for improved subcutaneous intramuscular or intradermal administration
SE9403915D0 (sv) * 1994-11-14 1994-11-14 Annelie Almstedt Process A
SE503424C2 (sv) * 1994-11-14 1996-06-10 Pharmacia Ab Process för rening av rekombinant koagulationsfaktor VIII
SE9501189D0 (sv) * 1995-03-31 1995-03-31 Pharmacia Ab Protein formulation
SE9503380D0 (sv) * 1995-09-29 1995-09-29 Pharmacia Ab Protein derivatives
PT1754718E (pt) 1996-04-24 2011-07-13 Univ Michigan Factor viii resistente à inactivação
US8183344B2 (en) 1996-04-24 2012-05-22 University Of Michigan Inactivation resistant factor VIII
US5851800A (en) * 1996-05-14 1998-12-22 Pharmacia & Upjohn Ab Process for producing a protein
EP0910581B1 (de) * 1996-06-24 2000-04-05 Max-Planck-Institut für Physiologische und Klinische Forschung Kerckhoff-Klink GmbH Verfahren zur affinitätschromatographischen aufreinigung von faktor viii
US6197526B1 (en) 1999-01-04 2001-03-06 Dyax Corp. Polypeptides for binding human factor VIII and fragments of human factor VIII
US7112438B2 (en) * 1999-01-04 2006-09-26 Dyax Corp. Binding molecules for human factor VIII and factor VIII-like proteins
EP1038959A1 (en) 1999-03-17 2000-09-27 Aventis Behring Gesellschaft mit beschränkter Haftung Factor VIII without B-domain, comprising one or more insertions of a truncated intron I of factor IX
SE9901379D0 (sv) 1999-04-19 1999-04-19 Pharmacia & Upjohn Ab Receptor structures
EP1233064A1 (en) 2001-02-09 2002-08-21 Aventis Behring Gesellschaft mit beschränkter Haftung Modified factor VIII cDNA and its use for the production of factor VIII
EP1421539B1 (en) 2001-06-14 2009-10-28 The Scripps Research Institute Stabilized factor viii with engineered disulfide bonds
EP1418810A4 (en) 2001-08-03 2006-08-02 Us Gov Health & Human Serv ORAL TREATMENT OF HEMOPHILIA
SI2574677T1 (sl) 2007-12-27 2017-11-30 Baxalta GmbH Procesi celične kulture
EP2704688B1 (en) * 2011-05-05 2019-07-10 Matinas BioPharma Nanotechnologies, Inc. Cochleate compositions and methods of making and using same

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS59184130A (ja) * 1983-03-31 1984-10-19 スクリツプス・クリニツク・アンド・リサ−チ・フアンデ−シヨン フアクタ−8凝固因子ポリペプチド類
JPS60185723A (ja) * 1984-01-12 1985-09-21 カイロン コーポレイション フアクタ−v3c組成物

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4361509A (en) * 1981-12-14 1982-11-30 Scripps Clinic And Research Foundation Ultrapurification of factor VIII using monoclonal antibodies
US4495175A (en) * 1982-08-05 1985-01-22 University Of Rochester Preparation of highly purified human antihemophilic factor
US4650858A (en) * 1983-03-21 1987-03-17 Nordisk Gentofte A/S Concentrate of the antihemophilic factor VIII and a process for producing it
US4710381A (en) * 1984-05-22 1987-12-01 The Blood Center Of Southeastern Wisconsin Method for maintaining intact, non-degraded factor VIII/von-Willebrand factor during blood processing
US4543210A (en) * 1984-10-04 1985-09-24 Miles Laboratories, Inc. Process for producing a high purity antihemophilic factor concentrate
SE8501050D0 (sv) * 1985-03-05 1985-03-05 Kabivitrum Ab Biologically active fragments of human antihemophilic factor and method for preparation thereof

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS59184130A (ja) * 1983-03-31 1984-10-19 スクリツプス・クリニツク・アンド・リサ−チ・フアンデ−シヨン フアクタ−8凝固因子ポリペプチド類
JPS60185723A (ja) * 1984-01-12 1985-09-21 カイロン コーポレイション フアクタ−v3c組成物

Also Published As

Publication number Publication date
DE3680368D1 (de) 1991-08-29
EP0197901B1 (en) 1991-07-24
US4749780A (en) 1988-06-07
EP0197901A1 (en) 1986-10-15
SE8501050D0 (sv) 1985-03-05
SG1893G (en) 1993-06-11
DK164282B (da) 1992-06-01
JPH0547524B2 (cg-RX-API-DMAC7.html) 1993-07-19
US4877614A (en) 1989-10-31
DK85786A (da) 1986-09-06
DK85786D0 (da) 1986-02-25
HK15293A (en) 1993-03-05
ATE65505T1 (de) 1991-08-15
CA1341497C (en) 2006-02-14

Similar Documents

Publication Publication Date Title
US4749780A (en) Biologically active fragments of human antihemophilic factor and method for preparation thereof
US4427646A (en) Use of radiolabeled peptide derived from crosslinked fibrin to locate thrombi in vivo
Deuel et al. Amino acid sequence of human platelet factor 4.
Sekiguchi et al. Domain structure of hamster plasma fibronectin: isolation and characterization of four functionally distinct domains and their unequal distribution between two subunit polypeptides
JP3701028B2 (ja) 高純度フォンビルブラント因子の入手方法
US4649132A (en) Treatment of Factor VIII inhibitors
JP2631127B2 (ja) フォン・ビルブラント因子の▲viii▼因子結合ドメイン
Misasi et al. Human complement factor H: An additional gene product of 43kDa isolated from human plasma shows cofactor activity for the cleavage of the third component of complement
Nilsson et al. Induction of split tolerance and clinical cure in high-responding hemophiliacs with factor IX antibodies.
DK165506B (da) Proteinpraeparat med koagulationsaktivitet samt fremgangsmaade til fremstilling deraf
EP0182372A2 (en) New factor VIII coagulant polypeptides
HU214905B (hu) Eljárás VIII. faktor izolálására
JPH0829089B2 (ja) フアクタ−▲viii▼凝固因子ポリペプチド類
US4831119A (en) Preparation for the treatment of hemophilia A inhibitor patients and a process for producing such a preparation
Abraham et al. Purification and properties of a human plasma endogenous modulator for the platelet tricyclic binding/serotonin transport complex
Rocha-Campos et al. Specific heterologous F (ab') 2 antibodies revert blood incoagulability resulting from envenoming by Lonomia obliqua caterpillars.
JPH02296A (ja) 8因子のフォン・ビルブラント因子結合ドメイン
Lundwall et al. Isolation of tryptic fragments of human C4 expressing Chido and Rodgers antigens
US4769336A (en) Treatment of factor VIII inhibitors
Medici et al. Improved method for purification of human platelet factor 4 by affinity and ion-exchange chromatography
CN103298483A (zh) 具有增加的比活性的抗血友病因子viii的新型变体
JPH01221393A (ja) 8因子阻害物質の処理
JPH01258700A (ja) 血液凝固第4因子の精製方法
JPH07224100A (ja) 新規トロンボモジュリン類
Hamaguchi et al. Biochemical study of protease inhibitors in normal chinchilla middle ear

Legal Events

Date Code Title Description
R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

EXPY Cancellation because of completion of term